Review





Similar Products

96
MedChemExpress epidermal growth factor
Epidermal Growth Factor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/pmc13091134-52-43-47?v=MedChemExpress
Average 96 stars, based on 1 article reviews
epidermal growth factor - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

99
NSJ Bioreagents egfr antibody / egf receptor
Egfr Antibody / Egf Receptor, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/custom%40v5390%4042390288?v=NSJ+Bioreagents
Average 99 stars, based on 1 article reviews
egfr antibody / egf receptor - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

91
Miltenyi Biotec mouse egf
Mouse Egf, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/bio_rxiv__64898__2026__06__21__733630-124-10-12?v=Miltenyi+Biotec
Average 91 stars, based on 1 article reviews
mouse egf - by Bioz Stars, 2026-08
91/100 stars
  Buy from Supplier

95
PromoCell c 39267 egf
C 39267 Egf, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/10__1016_slash_j__isci__2026__115886-272-114-112?v=PromoCell
Average 95 stars, based on 1 article reviews
c 39267 egf - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

97
R&D Systems recombinant human egf
Recombinant Human Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/pmc13091051-268-9-12?v=R%26D+Systems
Average 97 stars, based on 1 article reviews
recombinant human egf - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

86
Novoprotein egf
Egf, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/pm42280284-159-28-30?v=Novoprotein
Average 86 stars, based on 1 article reviews
egf - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

95
Miltenyi Biotec egf
A NichNet analysis of the cell-to-cell communication. Lymphocytes were set as the sender cell type and FAPs as the receiver cell type. Analysis was performed for each IIM subtype, as indicated, compared to NDC. Results are shown for the 20 ligands best predicting the FAP transcriptome, ranked by the Pearson correlation coefficient, indicating the ability of each ligand to predict target genes. The second column indicated the log fold change (LFC) for each gene in the lymphocyte cell cluster comparing each IIM subtype to NDC as indicated. The ligand–target matrix indicates the regulatory potential between ligands and target genes from the FAP transcriptome. B Feature plot indicating the expression of <t>EGF</t> in each group. The normalized gene expression is shown. C Representative immunofluorescence image of an IBM muscle biopsy. The target proteins are indicated. The scale bar shows 20 µm. ASYS anti-synthetase syndrome, FAP fibro-adipogenic progenitor, IBM inclusion body myositis, IMNM immune-mediated necrotizing myopathy, NDC non-diseased control, NOVA1 RNA-binding protein Nova1, EGF epidermal growth <t>factor,</t> <t>TGF</t> transforming growth factor.
Egf, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/pmc13263347-395-15-17?v=Miltenyi+Biotec
Average 95 stars, based on 1 article reviews
egf - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

86
Higeta Shoyu Co Ltd epidermal growth factor
A NichNet analysis of the cell-to-cell communication. Lymphocytes were set as the sender cell type and FAPs as the receiver cell type. Analysis was performed for each IIM subtype, as indicated, compared to NDC. Results are shown for the 20 ligands best predicting the FAP transcriptome, ranked by the Pearson correlation coefficient, indicating the ability of each ligand to predict target genes. The second column indicated the log fold change (LFC) for each gene in the lymphocyte cell cluster comparing each IIM subtype to NDC as indicated. The ligand–target matrix indicates the regulatory potential between ligands and target genes from the FAP transcriptome. B Feature plot indicating the expression of <t>EGF</t> in each group. The normalized gene expression is shown. C Representative immunofluorescence image of an IBM muscle biopsy. The target proteins are indicated. The scale bar shows 20 µm. ASYS anti-synthetase syndrome, FAP fibro-adipogenic progenitor, IBM inclusion body myositis, IMNM immune-mediated necrotizing myopathy, NDC non-diseased control, NOVA1 RNA-binding protein Nova1, EGF epidermal growth <t>factor,</t> <t>TGF</t> transforming growth factor.
Epidermal Growth Factor, supplied by Higeta Shoyu Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/pmc13191628-41-67-70?v=Higeta+Shoyu+Co+Ltd
Average 86 stars, based on 1 article reviews
epidermal growth factor - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

86
Fisher Scientific epidermal growth factor egf
A NichNet analysis of the cell-to-cell communication. Lymphocytes were set as the sender cell type and FAPs as the receiver cell type. Analysis was performed for each IIM subtype, as indicated, compared to NDC. Results are shown for the 20 ligands best predicting the FAP transcriptome, ranked by the Pearson correlation coefficient, indicating the ability of each ligand to predict target genes. The second column indicated the log fold change (LFC) for each gene in the lymphocyte cell cluster comparing each IIM subtype to NDC as indicated. The ligand–target matrix indicates the regulatory potential between ligands and target genes from the FAP transcriptome. B Feature plot indicating the expression of <t>EGF</t> in each group. The normalized gene expression is shown. C Representative immunofluorescence image of an IBM muscle biopsy. The target proteins are indicated. The scale bar shows 20 µm. ASYS anti-synthetase syndrome, FAP fibro-adipogenic progenitor, IBM inclusion body myositis, IMNM immune-mediated necrotizing myopathy, NDC non-diseased control, NOVA1 RNA-binding protein Nova1, EGF epidermal growth <t>factor,</t> <t>TGF</t> transforming growth factor.
Epidermal Growth Factor Egf, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egf/10__3390_slash_mps9030082-40-45-50?v=Fisher+Scientific
Average 86 stars, based on 1 article reviews
epidermal growth factor egf - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

Image Search Results


A NichNet analysis of the cell-to-cell communication. Lymphocytes were set as the sender cell type and FAPs as the receiver cell type. Analysis was performed for each IIM subtype, as indicated, compared to NDC. Results are shown for the 20 ligands best predicting the FAP transcriptome, ranked by the Pearson correlation coefficient, indicating the ability of each ligand to predict target genes. The second column indicated the log fold change (LFC) for each gene in the lymphocyte cell cluster comparing each IIM subtype to NDC as indicated. The ligand–target matrix indicates the regulatory potential between ligands and target genes from the FAP transcriptome. B Feature plot indicating the expression of EGF in each group. The normalized gene expression is shown. C Representative immunofluorescence image of an IBM muscle biopsy. The target proteins are indicated. The scale bar shows 20 µm. ASYS anti-synthetase syndrome, FAP fibro-adipogenic progenitor, IBM inclusion body myositis, IMNM immune-mediated necrotizing myopathy, NDC non-diseased control, NOVA1 RNA-binding protein Nova1, EGF epidermal growth factor, TGF transforming growth factor.

Journal: Cell Death & Disease

Article Title: Inflammation reprograms fibro-adipogenic progenitors to sustain immunopathogenic niches in myositis

doi: 10.1038/s41419-026-08966-w

Figure Lengend Snippet: A NichNet analysis of the cell-to-cell communication. Lymphocytes were set as the sender cell type and FAPs as the receiver cell type. Analysis was performed for each IIM subtype, as indicated, compared to NDC. Results are shown for the 20 ligands best predicting the FAP transcriptome, ranked by the Pearson correlation coefficient, indicating the ability of each ligand to predict target genes. The second column indicated the log fold change (LFC) for each gene in the lymphocyte cell cluster comparing each IIM subtype to NDC as indicated. The ligand–target matrix indicates the regulatory potential between ligands and target genes from the FAP transcriptome. B Feature plot indicating the expression of EGF in each group. The normalized gene expression is shown. C Representative immunofluorescence image of an IBM muscle biopsy. The target proteins are indicated. The scale bar shows 20 µm. ASYS anti-synthetase syndrome, FAP fibro-adipogenic progenitor, IBM inclusion body myositis, IMNM immune-mediated necrotizing myopathy, NDC non-diseased control, NOVA1 RNA-binding protein Nova1, EGF epidermal growth factor, TGF transforming growth factor.

Article Snippet: After reaching a confluence of 70 to 80%, the medium was supplemented with 10 ng/μL EGF (#130-093-825, Miltenyi Biotec) and 5 ng/μL TGF-β1 (#130-095-066, Miltenyi Biotec).

Techniques: Expressing, Gene Expression, Immunofluorescence, Control, RNA Binding Assay

A Two-sample ATAC-seq scatterplot. Each dot is a union peak (N = 139,260). Axes show log10(CPM + 1) for Control (x) and EGF + TGF-β (y). CPMs were derived from fragment counts per peak divided by library size, then log-transformed with a + 1 offset. Peaks were considered significant if the log2 fold change was ≥0.58. Three biological replicates were pooled per group. B Volcano plot indicating the transcription factor binding sites (TFBS) comparing EGF + TGF-β (treated) to vehicle (control). The x-axis is the effect size calculated as the change in the TFBS between groups. The y-axis is −log10( p value). The full list of results is in Suppl. File . C qPCR time-course for CCL2 and CXCL2. Mean ± SD of normalized expression over time for Control (blue), Primed (EGF + TGF-β; red), and Primed + SR11302 (gray). FAPs were exposed to EGF + TGF-β or vehicle at day 0 to 10 (priming) and 21 to 27 (re-challenge). N = 3 per group. CPM counts per million, EGF epidermal growth factor, TGF-β transforming growth factor beta.

Journal: Cell Death & Disease

Article Title: Inflammation reprograms fibro-adipogenic progenitors to sustain immunopathogenic niches in myositis

doi: 10.1038/s41419-026-08966-w

Figure Lengend Snippet: A Two-sample ATAC-seq scatterplot. Each dot is a union peak (N = 139,260). Axes show log10(CPM + 1) for Control (x) and EGF + TGF-β (y). CPMs were derived from fragment counts per peak divided by library size, then log-transformed with a + 1 offset. Peaks were considered significant if the log2 fold change was ≥0.58. Three biological replicates were pooled per group. B Volcano plot indicating the transcription factor binding sites (TFBS) comparing EGF + TGF-β (treated) to vehicle (control). The x-axis is the effect size calculated as the change in the TFBS between groups. The y-axis is −log10( p value). The full list of results is in Suppl. File . C qPCR time-course for CCL2 and CXCL2. Mean ± SD of normalized expression over time for Control (blue), Primed (EGF + TGF-β; red), and Primed + SR11302 (gray). FAPs were exposed to EGF + TGF-β or vehicle at day 0 to 10 (priming) and 21 to 27 (re-challenge). N = 3 per group. CPM counts per million, EGF epidermal growth factor, TGF-β transforming growth factor beta.

Article Snippet: After reaching a confluence of 70 to 80%, the medium was supplemented with 10 ng/μL EGF (#130-093-825, Miltenyi Biotec) and 5 ng/μL TGF-β1 (#130-095-066, Miltenyi Biotec).

Techniques: Control, Derivative Assay, Transformation Assay, Binding Assay, Expressing